On May 09, 2014, Trevena Inc (NASDAQ:TRVN), announced financial results for the quarter ended March 31, 2014. Cash and cash equivalents totaled $91.3 million as of March 31, 2014, compared to $38.0 million as of December 31, 2013. The increase reflects the net proceeds of $59.6 million received from the Company’s initial public offering in January 2014, offset by operating expenses. Trevena expects that its existing cash and cash equivalents will be sufficient to fund operations through the end of 2015. Trevena Inc (NASDAQ:TRVN), weekly performance is -6.64%. On last trading day company shares ended up $4.36. Analysts mean target price for the company is $15.00. Trevena Inc (NASDAQ:TRVN), distance from 50-day simple moving average (SMA50) is -32.10%.
On May 07, 2014, Targacept , Inc. (NASDAQ:TRGT), reported its financial results for the first quarter ended March 31, 2014. Targacept reported a net loss before income taxes of $11.6 million for the first quarter of 2014, compared to a net loss before income taxes of $8.1 million for the first quarter of 2013. As of March 31, 2014, cash and investments in marketable securities totaled $132.1 million. Targacept , Inc. (NASDAQ:TRGT), advanced 1.07% in last trading session and ended the day on $3.77. TRGT, return on assets is -35.50%. Targacept , Inc. (NASDAQ:TRGT), quarterly performance is -18.92%.
SIGA Technologies, Inc. (NASDAQ:SIGA), was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a note issued to investors on Monday,StockRatingsNetwork.com reports. They currently have a $2.70 price target on the stock. Zacks‘s price target suggests a potential downside of 2.00% from the company’s current price. SIGA Technologies, Inc. (NASDAQ:SIGA), shares moved up 0.37% in last trading session and was closed at $2.69, while trading in range of $2.61 – 2.73. SIGA Technologies, Inc. (NASDAQ:SIGA), year to date (YTD) performance is -17.74%.
On May 12, 2014, Onconova Therapeutics Inc (NASDAQ:ONTX), provided a corporate update and reported financial results for the first quarter ended March 31, 2014. Cash, cash equivalents, and marketable securities as of March 31, 2014 totaled $84.6 million, compared to $100.0 million as of December 31, 2013.Total net revenue was $0.4 million for the first quarter of 2014, compared to $1.1 million for the first quarter of 2013. Onconova Therapeutics Inc (NASDAQ:ONTX), ended the last trading day at $4.86. Company weekly volatility is calculated as 5.58% and price to cash ratio as 1.05. Onconova Therapeutics Inc (NASDAQ:ONTX), showed a negative weekly performance of 8.65%.
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), posted its quarterly earnings results on Monday. The company reported ($0.85) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.37) by $0.48, American Banking and Market Newsreports. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), weekly performance is -0.71%. On last trading day company shares ended up 33.80. Analysts mean target price for the company is $77.33. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), distance from 50-day simple moving average (SMA50) is -29.07%.